LENSAR Inc. Third Quarter 2026 Results Conference Call - LENSAR INC

Financial Performance:

• Total revenue for Q3 2026 was $14.1 million, a 1% year-over-year (YoY) decline from $14.3 million in Q3 2025, driven by a drop in capital system sales against a strong prior year.
• Recurring revenue grew 17% YoY to $12.6 million, representing 89% of total revenue (up from 75% a year ago).
• Procedure revenue surged 70% YoY to $9.2 million, while procedure volume increased 12% to 52,545 procedures.
• System revenue declined to $1.5 million from $3.5 million in the prior year.
• Gross margin expanded to 58% from 42% YoY, attributed to improved revenue mix and lower service costs.
• SG&A expenses decreased to $8.1 million from $12 million, primarily due to the absence of Alcon transaction-related costs in the prior year, partially offset by $1.2 million in strategic commercial investments.
• Operating loss narrowed significantly to $1.4 million from $7.6 million YoY.
• Net loss widened to $4.7 million from $3.7 million YoY, heavily impacted by a $3.4 million non-cash expense for warrant liability fair value changes (compared to a $7.7 million gain previously).
• Adjusted EBITDA turned positive at $1.7 million compared to a $0.3 million loss YoY.
• Cash and investments stood at $12.6 million as of September 30, 2026; the company incurred $900,000 in cash burn for the quarter.
• Liquidity was enhanced by securing a $10 million revolving line of credit, bringing total available liquidity to $22.6 million.

Guidance and Future Outlook:

• Management anticipates a ramp-up in commercial activity in Q4 2026 as overseas distributors re-engage following Alcon merger termination impacts and seasonal holiday lulls.
• A specific new feature, automated robotic docking capabilities, is scheduled for release by the end of Q1 2027.
• Long-term innovation roadmap includes a "femto-faco" integration (phacoemulsification with laser) expected within 18–24 months, contingent on strategic partnerships.
• Further platform expansions, including corneal procedures (flaps, LASIK, incisions) and integration with operating microscopes, are targeted for the 3–5 year horizon.
• Management expects cash burn to continue at approximately $2 million for the remainder of 2026 due to inventory and transaction fees, projecting a move toward break-even in 2027.
• The company remains focused on growing the installed base and increasing utilization rates as primary drivers of future growth.

Business Segments and Product Lines:

• The Ally robotic laser system is the core growth engine, with 10 systems placed in Q3 2026, bringing the global Ally installed base to ~225 systems and total laser installed base to ~450.
• 12 Ally systems remain in the backlog awaiting installation.
• 42% of installations over the last 12 months occurred with surgeons previously naive to femtosecond laser technology.
• Legacy Lensar laser customers migrating to the Ally platform typically see a 15–20% increase in procedure volume once trained.
• International markets (specifically Germany and Switzerland) are being reactivated after a hiatus caused by the Alcon deal uncertainty and subsequent reimbursement changes.
• Revenue mix is shifting heavily toward recurring sources (lease/service and procedure revenue) rather than one-time capital sales.

Market and Competitive Landscape:

• Market share increased to 24.5% in Q3 2026 from 24.1% in Q2, driven by competitive switching and new surgeon adoption.
• The broader cataract surgery market experienced a slight volume decline for the first time in history, though Lensar's procedure volume grew 12% YoY, outpacing the general market.
• Reimbursement pressure in the US and abroad is driving surgeon demand for high-efficiency, advanced technology procedures like those enabled by Ally.
• Key competitive differentiator is the "surgeon-centric" model that offers better patient outcomes and practice efficiency.

Risks and Challenges:

• Seasonality remains a significant factor, with Q3 historically the slowest quarter due to summer vacations and holiday scheduling.
• Global cataract market volume contraction poses a headwind to overall system placement demand.
• Geopolitical and regulatory reimbursement changes in key international markets (e.g., Germany, Switzerland) caused temporary sales halts and require navigation.
• The termination of the Alcon transaction disrupted international distribution relationships, requiring significant effort to re-establish momentum.
• Cash flow constraints related to inventory investment and transaction fee payments in the remainder of 2026.

Management Commentary and Tone:

• Management maintained a confident but realistic tone, acknowledging the seasonal slowdown and the impact of the Alcon transaction on prior comparisons.
• The narrative emphasizes "foundational health" over quarterly sales volume, focusing on the durability of recurring revenue and installed base growth.
• Executives expressed strong optimism regarding the "re-jump-starting" of overseas markets and the pipeline of innovation.
• Nick Curtis emphasized that the long-term value lies in utilization and practice integration rather than just unit placements.
• Mike Rossi highlighted improved operational discipline, noting the significant narrowing of the operating loss.

Analyst Questions and Answers:

• Alex Nowak (Lucid Capital Markets): Asked about the backlog and CapEx market dynamics. Management responded that the slowdown was due to the Alcon deal fallout, summer holidays, and foreign reimbursement changes, but activity is rebounding strongly in key markets like Germany. Future innovation will focus on automation/robotics and expanded corneal capabilities.
• Ryan Zimmerman (BTIG): Inquired about US vs. OUS procedure dynamics and margin drivers. Management confirmed the US market is ahead in adoption and reimbursement; OUS is a "work in progress" with expected robust growth in mid-2027. Margins were high due to favorable US mix and lower service activity.
• Wes Villegas (Lake Street Capital Markets): Asked about upgrading legacy customers to Ally and cash flow trends. Management noted a consistent 15–20% volume lift post-migration and predicted cash burn of ~$2M for the rest of 2026, with a path to break-even in 2027. They also clarified that overseas redeployment of legacy units will support global install base growth.

Other Key Points:

• The call took place on November 10, 2026, covering the period ended September 30, 2026.
• A $3.4 million non-cash warrant liability expense significantly impacted the net loss figure but not cash operations.
• The company showcased new robotic docking capabilities at the AAO Annual Meeting during the quarter, generating high surgeon interest.
• 450 total systems are installed globally, with 225 being the newer Ally platform.
• The company is actively exploring strategic relationships for hardware integrations (phacoemulsification, microscopes) to expand the Ally workstation capabilities.